-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...
More »SEARCH RESULT
European Union-India FTA may hit generic medical industry-Rema Nagarajan
-The Times of India The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade...
More »European Parliament rejects Anti-Counterfeiting Trade Agreement-Ankur Paliwal
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries It was a triumphant moment for public health campaigners when members of the European Parliament voted against the Anti- Counterfeiting Trade Agreement (ACTA) on July 4. ACTA is a plurilateral pact, designed to protect against counterfeiting of products, including medicines. ACTA, primarily drafted and secretly negotiated by the US, was signed on October...
More »On WHO agenda: a global vaccine action plan-Sonal Matharu
Health activists say new policy may not address the weaknesses in ongoing routine immunisation programmes and would flood poor countries with new vaccines When the global health leaders meet in Geneva from May 21 to 26 for the World Health Organization's 65th General Assembly, introducing new vaccines in the low- and middle-income countries would be high on their agenda. A “global draft vaccine action plan”, available on WHO's website, details the implementation...
More »Question of efficacy -Leena Menghaney
The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »